Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciae126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The use of ceftobiprole in treatment pathways in Spain: An expert panel review.
J Glob Antimicrob Resist
June 2025
Hospital Universitario 12 de Octubre, Madrid, CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III (CIBERINFEC), Madrid, Spain.
Objectives: Ceftobiprole is a fifth-generation β-lactam approved in Spain solely for the treatment of community- and hospital-acquired pneumonia. The objectives of this study were to discuss the use of ceftobiprole in the Spanish healthcare setting, and to review and define its positioning for the treatment of infections, both in the hospital and outpatient settings.
Methods: In November 2023, an in-person meeting was held, with 10 healthcare professionals with expertise in infectious diseases and/or hospital-at-home settings in attendance.
The Positioning of Ceftobiprole in the Treatment of Staphylococcus aureus Bacteremia.
Clin Infect Dis
December 2024
Division of Infectious Diseases, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
The Positioning of Ceftobiprole in Staphylococcus aureus Bacteremia.
Clin Infect Dis
December 2024
Infectious Diseases Unit, Hospital Virgen de las Nieves, Granada, Spain.
Ceftobiprole is a broad-spectrum, fifth-generation cephalosporin currently approved for community-acquired and non-ventilator-associated hospital-acquired pneumonia. High bactericidal and anti-biofilm activity has been exhibited in in vitro and animal models. This, together with its synergism with other antibiotics against gram-positive bacteria, makes it an ideal candidate for treatment of complex infections, such as those associated with devices or infective endocarditis.
View Article and Find Full Text PDFCeftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother
May 2015
Division of Infectious Disease, Department of Medicine, San Francisco General Hospital, San Francisco, California, USA.
The role of mecA mutations in conferring resistance to ceftobiprole and ceftaroline, cephalosporins with anti-methicillin-resistant Staphylococcus aureus (MRSA) activity, was determined with MRSA strains COL and SF8300. The SF8300 ceftaroline-passaged mutant carried a single mecA mutation, E447K (E-to-K change at position 447), and expressed low-level resistance. This mutation in COL conferred high-level resistance to ceftobiprole but only low-level resistance to ceftaroline.
View Article and Find Full Text PDF